Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
RNA binding motif protein 15
(
RBM15
) was originally described as a 5' translocation partner of the MAL gene in t(1;22)(p13;q13)infant acute megakaryocytic leukemia. Although previous investigations have shown that Rbm15 has broad regulatory effects within murine hematopoiesis through modulating Notch-induced transcriptional activation, which plays key roles in leukemogenesis, it is not clear what the functions of
RBM15
are in the regulation of hematological malignancies. In the present study, we show that
RBM15
expression was significantly increased in patients with blast-crisis
chronic myelogenous leukemia
(
CML
) compared with chronic-phase or accelerated-phase disease by real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. To further elucidate the role of
RBM15
in
CML
, we introduced
RBM15
small interfering RNA (siRNA) using pSUPER into
CML
cells. Fluorescence activated cell sorting (FACS), real-time RT-PCR and Western blot were used to study changes in
RBM15
expression levels in transduced cells by comparing with control cells. Decreasing
RBM15
levels with RNA interference could inhibit the growth and proliferation, block the cell cycle and induce apoptosis in
CML
cells. Knockdown of
RBM15
may also act to inhibit clonogenicity and induce differentiation of
CML
cells along the myeloid lineage. Our studies also show that the effects of
RBM15
on
CML
cells may be mediated, at least in part, via its effect on Notch signaling. These findings demonstrate that
RBM15
does indeed play a critical role in the survival of
CML
cells, which may have potential application in designing molecular therapies for
CML
treatment.
...
PMID:Biological effects of decreasing RBM15 on chronic myelogenous leukemia cells. 2249 98